Introduction {#sec1}
============

Immediate myocardial revascularization is the mainstay of the current management of ST-elevation myocardial infarction (STEMI) patients \[[@cit0001]\]. This results in a reduction of the extent of infarction or even allows significant myocardial damage to be avoided. Despite modern management, segmental left ventricular wall motion abnormalities are seen in some patients. Although it is usually not necessary to determine prospects of full functional recovery immediately, evaluation of myocardial viability is of key importance in some clinical situations.

A diagnostic test used commonly to evaluate whether post-infarction left ventricular dysfunction is permanent or associated with reversible myocardial stunning or hibernation is low-dose dobutamine echocardiography (LDDE) \[[@cit0002], [@cit0003]\]. In comparison to other modalities, which may serve the same purpose, including cardiovascular magnetic resonance (CMR) and single-photon emission computed tomography (SPECT) myocardial perfusion scintigraphy, LDDE is less expensive and more available. Compared to other imaging methods and nuclear medicine techniques, technical aspects of LDDE may limit the ability to obtain good quality images (in about 10% of patients). New techniques based on three-dimensional imaging \[[@cit0004], [@cit0005]\] and the use of ultrasound contrast agents improve the diagnostic value of stress echocardiography compared to CMR and SPECT \[[@cit0006], [@cit0007]\].

However, the safety of exposing damaged myocardium to large ultrasound beam volumes during contrast-enhanced three-dimensional echocardiography has not been established.

The aim of our study was to compare the utility and safety of three-dimensional contrast low-dose dobutamine echocardiography (3DCLDDE) and the conventional diagnostic LDDE protocol.

Material and methods {#sec2}
====================

The study was performed in the First Chair and Department of Cardiology, Medical University of Warsaw. The study protocol was approved by the Bioethics Committee at the Medical University of Warsaw. We studied 100 consecutive patients after STEMI, treated according to the Polish and European Society of Cardiology guidelines \[[@cit0001]\]. The study group included 61 patients after a first myocardial infarction treated invasively. Despite percutaneous coronary intervention, segmental left ventricular wall motion abnormalities were seen in 37 patients at 7 days after revascularization. To determine prospects of left ventricular function recovery in these patients, we evaluated myocardial viability by dobutamine echocardiography between the 7^th^ and 10^th^ day of the hospital stay using the evaluated protocol (3DCLDDE group) that included contrast-enhanced three-dimensional (3D) and two-dimensional (2D) echocardiography. The control group (LDDE) included 39 patients after a myocardial infarction in whom myocardial viability was evaluated by conventional dobutamine stress 2D echocardiography. Alternating allocation was used to assign patients to the 3DCLDDE or LDDE group.

Echocardiographic examinations were performed using a Philips iE33 system with s5-1, x3-1, and x5-1 probes (Philips, Andover, Massachusetts, USA) and recorded digitally.

According to the study protocol, all patients underwent a complete, typical resting echocardiography. Left ventricular ejection fraction was calculated using the biplane modified Simpson method.

The protocol of dobutamine echocardiography in the 3DCLDDE group included recording of 2D images in the LAX, SAX, AP4C, and AP2C, and 3D images at baseline, at every 5 min of dobutamine infusion at the rate of 5, 10, and 20 μg/kg body weight/min, and at 10 min after termination of the dobutamine infusion. At baseline and at peak dose, a slow bolus of an echocardiographic contrast agent (sulfur hexafluoride -- SonoVue, Bracco) was administered. 2D images were recorded before and after contrast microbubble destruction using a low mechanical index (MI 0.1) ultrasound beam. A high mechanical index ultrasound impulse (Flash, MI 1.2) lasting for 3 cardiac cycles was used to destroy contrast microbubbles and image myocardial perfusion. 3D images were recorded in the full volume mode, and contrast microbubble destruction was obtained by increasing the mechanical index manually to the maximum values.

In the control group the echocardiographic examinations did not include 3D image recording and contrast agent administration, which is a standard for LDDE tests.

Following dobutamine echocardiography, left ventricular wall motion was evaluated using a 17-segment model. The wall motion score index (WMSI) was calculated using the obtained data.

Five-year survival was verified using the electronic PESEL/eWUŚ database of the National Health Fund.

Statistical analysis {#sec2.1}
--------------------

Statistical analysis was performed using the SAS 9.2/JMP 12 software. Quantitative variables were expressed as mean values ± standard deviation, and qualitative variables as percentages. Normal distribution of the quantitative variables was confirmed using the Kolmogorov-Smirnov test. Between-group comparisons were performed using the Student *t* test for normally distributed quantitative variables, the Mann-Whitney test for non-normally distributed quantitative variables, and the Fisher test for categorical variables.

Results {#sec3}
=======

The study and control groups were of a similar size. A non-significantly larger proportion of men was noted in the study group, while patients in the control group were older. The baseline clinical characteristics of both groups were comparable. Five-year survival was 89% in the 3DCLDDE group and 87% in the control group ([Table I](#t0001){ref-type="table"}).

###### 

Study and control group characteristics

  -------------------------------------------------------------------
  Parameter         3DCLDDE            LDDE               *P*-value
  ----------------- ------------------ ------------------ -----------
  Age               56 ±11\            62 ±9.3\           0.001
                    (95% CI: 52--60)   (95% CI: 59--65)   

  Men               28 (75%)           24 (61%)           0.18

  Hypertension      20 (54%)           23 (59%)           0.66

  Diabetes          8 (21%)            9 (22%)            0.87

  Dyslipidemia      18 (53%)           20 (51%)           0.81

  B-blockers        12 (32%)           14 (35%)           0.75

  ACEi              15 (40%)           17 (43%)           0.78

  STEMI anterior    25 (67%)           25 (64%)           0.75

  5-year survival   33 (89%)           34 (87%)           0.13
  -------------------------------------------------------------------

Basic cardiac dimensions did not differ between the two groups, except for left atrial size and intraventricular septum diastolic dimension (IVSd), which was slightly but significantly higher in the control group ([Table II](#t0002){ref-type="table"}).

###### 

Comparison of baseline echocardiographic parameters

  Parameter     3DCLDDEMean, standard deviation(95% CI)   LDDEMean, standard deviation(95% CI)   *P*-value
  ------------- ----------------------------------------- -------------------------------------- -----------
  LVDd \[cm\]   5.1 ±0.5 (4.9--5.2)                       5.3 ±0.6 (5.2--5.6)                    0.11
  IVSd \[cm\]   1.2 ±0.2 (1.0--1.2)                       1.1 ±0.1 (1.0--1.1)                    \< 0.05
  PWDt \[cm\]   1.0 ±0.2 (1.0--1.2)                       1.0 ±0.1 (0.9--1.0)                    0.58
  RV \[cm\]     2.5 ±0.3 (2.4--2.6)                       2.6 ±0.4 (2.4--2.7)                    0.22
  Ao \[cm\]     3.0 ±0.5 (2.9--3.2)                       3.2 ±0.5 (3.0--3.4)                    0.08
  LA \[cm\]     3.6 ±0.5 (3.4--3.7)                       4.1 ±0.5 (3.9--4.3)                    0.03
  EF (%)        47 ±8.9 (43--49)                          44 ±9.5 (41--47)                       0.14

Both groups were comparable in terms of dobutamine echocardiography parameters ([Table III](#t0003){ref-type="table"}).

###### 

Comparison of dobutamine echocardiography parameters in the two groups

  Parameter                                3DCLDDEMean, standard deviation(95% CI)   LDDEMean, standard deviation(95% CI)   *P*-value
  ---------------------------------------- ----------------------------------------- -------------------------------------- ------------
  WMSI at rest                             1.36 ±0.14 (1.31--1.41)                   1.41 ±0.23 (1.33--1.48)                0.34
  WMSI at peak dose                        1.21 ±0.18 (1.27--1.15)                   1.27 ±0.2 (1.2--1.34)                  0.32
  WMSI increase                            0.15 ±0.09 (0.12--0.18)                   0.17 ±0.24 (0.09--0.25)                0.58
  Maximum dobutamine dose                  19.7 ±4.6 (18--21)                        22.7 ±7.0 (20--25)                     0.052
  Duration of dobutamine test              11.3 ±2.5 (10--12)                        12.1 ±3.3 (11--13)                     0.35
  Resting heart rate                       68 ±10 (65--72)                           64 ±10 (60--61)                        0.06
  Resting blood pressure                   116 ±15 (111--121)/67 ±9 (64--70)         126 ±12 (121--130)/71 ±10 (68--74)     0.009/0.11
  Heart rate at peak dose                  82 ±18 (75--87)                           87 ±23 (79--94)                        0.31
  Blood pressure at peak dose              131 ±23 (123--138)/70 ±12 (66--70)        149 ±24 (141--157)/71 ±12 (67--75)     0.005/0.73
  Contrast agent dose per patient \[ml\]   5.4                                       --                                     --

Wall motion score index both at rest and at peak dose, WMSI increase, duration of the dobutamine test, dobutamine dose, and heart rate and diastolic blood pressure at baseline and at peak workload did not differ significantly between the two groups. Higher systolic blood pressure at rest and at peak dobutamine dose was seen in the control group.

Single ventricular ectopic beats were observed during dobutamine testing in 1 patient in the study group. In the control group, chest pain with a rise in blood pressure was seen in 1 patient, complex ventricular arrhythmia was noted in 2 patients, and single ectopic beats were observed in another 2 patients ([Table IV](#t0004){ref-type="table"}).

###### 

Comparison of dobutamine echocardiography adverse effects in the two groups

  Parameter     3DCLDDE   LDDE   *P*-value
  ------------- --------- ------ -----------
  SVPB          0         0      NA
  Single VPB    1         2      1
  Complex VPB   0         2      0.49
  Dyspnea       0         1      1
  Chest pain    0         1      1

Discussion {#sec4}
==========

Low-dose dobutamine echocardiography has been used for many years to identify viable myocardium in patients with post-infarction left ventricular dysfunction \[[@cit0008]\]. Many authors indicate that this technique is relatively safe and associated with a low risk of complications \[[@cit0009]\]. Similar conclusions may be arrived at based on our findings.

However, LDDE has some ultrasonographic limitations due to not always ideal tissue ultrasound translucency and the quality of acoustic windows used to obtain typical echocardiographic views. Echocardiographic contrast agents that were introduced more than 20 years ago allowed endocardial visualization and evaluation of tissue perfusion to be improved \[[@cit0010]--[@cit0012]\] even in patients with technically difficult imaging conditions.

After several years of use of these agents, questions arose regarding their safety. A few reports were published describing significant complications that might have (but also might not have) been related to administration of echocardiographic contrast agents. Based on these reports, warnings on the use of echocardiographic contrast agents were released by drug regulatory agencies in 2007 (FDA -- [www.fda.gov](www.fda.gov); EMA -- [www.ema.europa.eu](www.ema.europa.eu)).

However, as early as in 2008 Wei *et al.* \[[@cit0013]\] performed a retrospective multicenter study to evaluate infusion of about 80,000 doses of echocardiographic contrast agents (Optison, Definity). This analysis included 10,000 cases in which these agents were administered to critically ill patients, and about 28% of contrast-enhanced studies were stress tests. The only adverse effects definitely associated with administration of a contrast agent were anaphylactic reactions in 4 (0.006%) patients, and 8 patients presented symptoms that might have been associated with administration of a contrast agent. Senior *et al.* arrived at similar conclusions regarding safety of the SonoVue contrast agent \[[@cit0014]\]. Following publication of many similar reports, absolute contraindications to the use of contrast agents in patients after a myocardial infarction were withheld, and cardiac societies allowed their use \[[@cit0015]\].

In our study, similarly to large multicenter analyses, we noted a very low rate of adverse events that might have been, but was not necessarily, directly associated with the use of a contrast agent.

In the study group, one element of the study protocol was to perform a three-dimensional recording of contrast agent flow. A short ultrasound impulse (flash) was used to reset the perfusion image by contrast microbubble destruction, resulting in their content being released to the coronary circulation. This situation occurs typically during two-dimensional contrast myocardial perfusion echocardiography, which is considered a safe diagnostic technique \[[@cit0016]--[@cit0019]\], even when taking into account potential genotoxic changes \[[@cit0020]\]. In our study, however, we used a three-dimensional ultrasound beam which increased the amount of the contrast agent undergoing microbubble destruction at the same time. This potentially increases the amount of contrast agent reaching dysfunctional myocardium. However, our study showed that three-dimensional contrast echocardiography is safe even in patients after a recent acute coronary event.

Although the patients in the LDDE group were slightly older, this should not have an impact on the study results \[[@cit0021]\]. The septum in diastole was slightly thicker in the study group, whereas the left atrial dimension was slightly larger in the control group. These observations did not correlate with the prevalence of hypertension, which was comparable in both groups. The baseline systolic blood pressure was in the normal range in both groups, but it was higher in the control group. Peak dose dobutamine systolic pressure was slightly higher in the control group. However, these observations were in the expected range \[[@cit0022]\].

Due to the high cost of dedicated contrast study equipment, a dedicated infusion pump was not used for administration of a contrast agent.

The study was performed in a single cardiology unit, which resulted in a reduced capability to recruit patients due to an increased availability of percutaneous coronary revascularization.

Five-year survival in patients evaluated using the study protocol was 89%, slightly higher compared to the control group (87%), which may indirectly indicate that clinical management decisions based on these tests were appropriate.

In conclusion, use of small amounts of a contrast agent that are sufficient to opacify the left ventricle and evaluate myocardial perfusion does not increase the risk of adverse effects during three-dimensional contrast-enhanced stress dobutamine echocardiography in hemodynamically stable patients early after an acute myocardial infarction.
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